IX Takes Part in IPVS 2026 to Learn from Global Priorities and Partner to Advance HPV Prevention
Athens, Greece (ANTARA/PRNewswire) – Xiamen Innovax Biotech Co., Ltd. (IX) took part in the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), held in Athens, Greece, from 22 to 25 October 2026. At the event, IX met experts and partners from various countries to exchange scientific knowledge and discuss opportunities for collaboration in HPV prevention and the elimination of cervical cancer.
Under the theme “Together Against HPV”, IX welcomed delegates from around the world at Booth 14 to discuss vaccine innovation, scientific evidence, vaccine access and international cooperation. IX also presented an interactive signature board and message wall, inviting delegates to share their views and commitments on HPV prevention.
Recognising the varied public health needs and challenges in different countries, IX stressed the importance of listening to diverse perspectives, understanding local conditions, and turning scientific innovation into affordable and sustainable solutions.
Latest Interim Data Presented at IPVS 2026
During a scientific session, Dr Nana A. Ansah of the Navrongo Health Research Centre in Ghana presented a six-month interim analysis from the PATH study titled “Single-dose HPV Immunobridging Study with New Vaccines” (SHINE I; CVIA 104).
The multi-country Phase III study uses a randomised, double-blind design and is being conducted in Ghana and the Philippines. It compares the immunogenicity and safety of a single dose of Cecolin 9, an HPV vaccine, with Gardasil 9 in girls aged 9–14 and young women aged 15–20. Final results are expected in 2028.
From Innovation to Global Collaboration
IX’s HPV vaccine portfolio includes Cecolin, a bivalent HPV vaccine that has received prequalification from the World Health Organization (WHO), and Cecolin 9, a next-generation nine-valent HPV vaccine launched in China in 2025.
Drawing on its proprietary E. coli-based virus-like particle (VLP) technology platform, IX continues to advance vaccine innovation, expand production capacity and strengthen international partnerships. Through technology transfer and local capacity-building, the company aims to maintain a sustainable vaccine supply while ensuring that innovation is better suited to local public health needs.
IX’s participation in IPVS 2026 reaffirmed its commitment to listening, learning and working with the global HPV community. The company aims to provide high-quality vaccines at affordable prices and will continue to expand partnerships in different countries to strengthen HPV prevention and support the global goal of eliminating cervical cancer.
Source: jawawa.id (https://jawawa.id/newsitem/ix-takes-part-in-ipvs-2026-to-learn-from-global-priorities-and-partner-to-advance-hpv-prevention-1793260430)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5818879/partisipasi-ix-di-ajang-ipvs-2026-mempelajari-aspirasi-global-bermitra-guna-mendorong-pencegahan-hpv), translated from Indonesian